4 news items
Syros Reports First Quarter 2024 Financial Results and Provides a Corporate Update
SYRS
14 May 24
the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug
Syros Receives Fast Track Designation from the FDA for Tamibarotene for the Treatment of Newly Diagnosed Unfit AML with RARA gene overexpression
SYRS
9 Apr 24
; demonstrate in any current and future clinical trials the requisite safety, efficacy and combinability of its drug candidates; sustain the response
Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
SYRS
27 Mar 24
the requisite safety, efficacy and combinability of its drug candidates; sustain the response rates and durability of response seen to date with its drug
Syros Announces Completion of Enrollment of 190 Patients Necessary to Support Primary Endpoint Analysis in SELECT-MDS-1 Phase 3 Trial
SYRS
25 Mar 24
drug candidates; sustain the response rates and durability of response seen to date with its drug candidates; successfully develop a companion
- Prev
- 1
- Next